Top Markets
Coin of the day
Sensorion SA Sensorion SA

Sensorion SA

ALSEN
Rang in aandelen #13314
Sensorion SA, a clinical-stage biopharmaceutical company, develops drug... Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.
Aandeelprijs
$0.30780727
Marktkapitalisatie
$94.19M
Verandering (1 dag)
-0.19%
Verandering (1 jaar)
-34.73%
Land
FR
Handel Sensorion SA (ALSEN)

Categorie

Aandelsplitsingen voor Sensorion SA (ALSEN)
Het aandeel Sensorion SA (symbool: ALSEN) heeft in totaal 0 splitsingen ondergaan.
De meest recente splitsing vond plaats op Jul 13, 2026.
Eén aandeel ALSEN dat vóór Jul 13, 2026 werd gekocht, staat nu gelijk aan 0 aandelen ALSEN.
Lijst van aandelen splitsingen
Jaar Splitsing Vermenigvuldiging Cumulatieve vermenigvuldiging
Niet genoeg gegevens voor de verstrekte datums.
Aandelsplitsingen van vergelijkbare bedrijven of concurrenten
Bedrijf Aantal aandelen splitsingen Cumulatieve vermenigvuldiging Land
5 x199
DK
1 x2
US
0 -
US
0 -
BE
0 -
NL